Skip to main content
    C

    CytomX Therapeutics Inc (CTMX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.99
    -0.06 (-2.70%)

    Market Cap: $444.73M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    CytomX Therapeutics Inc (CTMX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to CytomX Therapeutics are Cullinan Oncology LLC (CGEM), CorMedix (CRMD) and Candel Therapeutics (CADL). By market cap, CytomX Therapeutics ranks 8th of the 13 companies on this page; Kura Oncology (KURA) is the largest at $713.90M.

    Peer Comparison

    CTMX's ROIC of -32.8% is below the peer median of -14.9%, and its revenue growth of -71.7% is below the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    CytomX Therapeutics (CTMX)$444.73MN/A31.0x0.0%-32.8%-71.7%0.00%
    Cullinan Oncology LLC (CGEM)$667.39MN/AN/A0.0%N/A0.0%0.00%
    CorMedix Inc (CRMD)$370.64M6.3x0.9x15.5%13.9%-47.7%0.00%
    Candel Therapeutics Inc (CADL)$486.37MN/AN/A0.0%-43.5%0.0%0.00%
    Immix Biopharma Inc (IMMX)$657.09MN/AN/A0.0%-14.9%0.0%0.00%
    Puma Biotechnology Inc (PBYI)$401.70M15.0x1.6x10.3%N/A1.1%0.00%
    Gyre Therapeutics Inc. (GYRE)$471.74MN/A3.8x-22.7%N/A0.7%0.00%
    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)$387.16MN/AN/A0.0%N/A0.0%0.00%
    Tevogen Bio Holdings Inc. (TVGN)$406.59MN/AN/A0.0%2022.8%0.0%0.00%
    Fulcrum Therapeutics Inc (FULC)$287.96MN/AN/A0.0%N/A-100.0%0.00%
    Phathom Pharmaceuticals Inc (PHAT)$492.63MN/A1.8x-30.2%11.4%71.1%0.00%
    Kura Oncology Inc (KURA)$713.90MN/A8.0x0.0%-1125.3%10.1%0.00%
    Olema Pharmaceuticals Inc (OLMA)$662.30MN/AN/A0.0%-53.8%0.0%0.00%
    Peer median$479.05M10.7x1.8x0.0%-14.9%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to CytomX Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Cullinan Oncology LLC (CGEM)
    Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients...
    CGEM competitors
    CorMedix Inc (CRMD)
    CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious...
    CRMD competitors
    Candel Therapeutics Inc (CADL)
    Candel Therapeutics Inc. is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary oncolytic virus platform...
    CADL competitors
    Immix Biopharma Inc (IMMX)
    Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology...
    IMMX competitors
    Puma Biotechnology Inc (PBYI)
    Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States...
    PBYI competitors
    Gyre Therapeutics Inc. (GYRE)
    Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases.
    GYRE competitors
    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
    Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies...
    CTNM competitors
    Tevogen Bio Holdings Inc. (TVGN)
    Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology...
    TVGN competitors
    Fulcrum Therapeutics Inc (FULC)
    Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined...
    FULC competitors
    Phathom Pharmaceuticals Inc (PHAT)
    Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
    PHAT competitors
    Kura Oncology Inc (KURA)
    Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States.
    KURA competitors
    Olema Pharmaceuticals Inc (OLMA)
    Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development...
    OLMA competitors

    Frequently Asked Questions About CTMX

    Who are CytomX Therapeutics' main competitors?

    The companies most similar to CytomX Therapeutics include Cullinan Oncology LLC (CGEM), CorMedix (CRMD), Candel Therapeutics (CADL), Immix Biopharma (IMMX) and Puma Biotechnology (PBYI), listed from the closest match.

    Who is CytomX Therapeutics' biggest competitor?

    Kura Oncology (KURA) is the largest of the similar companies at $713.90M; Cullinan Oncology LLC (CGEM) is the closest match by business profile, size, sector and industry.

    How does CTMX stock compare with its competitors?

    CTMX's P/S is 31.0x against a peer median of 1.8x; its net margin is 0.0% against a peer median of 0.0%.

    Which of CytomX Therapeutics' competitors pays a higher dividend?

    CytomX Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is CytomX Therapeutics bigger than its competitors?

    No. CytomX Therapeutics is 8th by market cap among the 13 companies on this page; the largest is Kura Oncology (KURA) at $713.90M.